These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30804480)

  • 1. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
    Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
    Nat Nanotechnol; 2019 Apr; 14(4):388-397. PubMed ID: 30804480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 loss creates therapeutic vulnerability in colorectal cancer.
    Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
    Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin Bicarbonate-Mediated Efficient RNAi for Precise Targeting of
    Xu J; Liu Y; Liu S; Ou W; White A; Stewart S; Tkaczuk KHR; Ellis LM; Wan J; Lu X; He X
    Nano Today; 2022 Apr; 43():. PubMed ID: 35251293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer.
    Dong Y; Liao H; Fu H; Yu J; Guo Q; Wang Q; Duan Y
    ACS Appl Mater Interfaces; 2019 Oct; 11(42):38417-38428. PubMed ID: 31556584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
    Chen G; Wang Y; Xie R; Gong S
    J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
    Valcourt DM; Dang MN; Scully MA; Day ES
    ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
    Synnott NC; O'Connell D; Crown J; Duffy MJ
    Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release.
    Stras S; Howe A; Prasad A; Salerno D; Bhatavdekar O; Sofou S
    Mol Pharm; 2020 Jan; 17(1):118-131. PubMed ID: 31825626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
    Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
    Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA.
    Zhang L; Mu C; Zhang T; Yang D; Wang C; Chen Q; Tang L; Fan L; Liu C; Shen J; Li H
    J Nanobiotechnology; 2021 Jan; 19(1):13. PubMed ID: 33413427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
    Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
    Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
    Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
    Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of ERK5 targeting in triple negative breast cancer.
    Ortiz-Ruiz MJ; Álvarez-Fernández S; Parrott T; Zaknoen S; Burrows FJ; Ocaña A; Pandiella A; Esparís-Ogando A
    Oncotarget; 2014 Nov; 5(22):11308-18. PubMed ID: 25350956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.